Snapshot
Halozyme Therapeutics, Inc. reported $326M of revenue in Q2 2025, up 40.8% year over year, with diluted EPS of $1.33 and an operating margin of 62.2%.
- Revenue
- $326M
- YoY growth
- +40.8%
- Diluted EPS
- $1.33
- Operating margin
- 62.2%
$326M
Revenue
+40.8%
YoY growth
$1.33
Diluted EPS
62.2%
Operating margin
01 Key takeaways
What management said
- •Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business, and Nicole LaBrosse, our Chief Financial Officer, will review our financial results as well as our outlook.
- •Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation.
- •I'm pleased to announce another record quarter, which highlights the significant growth and accelerating momentum we have across the business.
- •Total revenue in the quarter was $326 million, representing a 41% increase over the second quarter of the prior year.
- •This robust growth was driven by continued strong royalty revenue performance, driven by our three established blockbuster subcutaneous therapies, Darzalex subcutaneous, subcutaneous Phesgo, and Vyvgart Hytrulo.
- •This quarter's royalty revenue grew an impressive 65% year-over-year to $206 million.
- •Adjusted EBITDA increased an outstanding 65% over the prior year's second quarter to $226 million.
- •This was driven by the accelerating growth of our high-margin royalty revenue streams, as a result of increasing demand for products, incorporating our leading drug delivery technology, ENHANZE.
- •Based on this strong continued performance and the growth trends, I am pleased to announce that we are raising our 2025 financial guidance for the second time this year.
- •We are now projecting total revenue of $1.275 billion-$1.355 billion, representing 26%-33% growth over 2024.
- •This is a further increase to revenue guidance of $75 million, after raising guidance by approximately $50 million in the first quarter reporting.
- •2025 full-year royalty revenue guidance has increased to $825 million-$860 million, representing growth year-over-year of 44%-51%.
SourcesCompany financials · earnings call
Last updated